Research Information Only — Educational content, not medical advice. Both carry a cancer caution and require physician oversight.
PeptideReport.ai
Compare › BPC-157 vs GHK-Cu

Head-to-Head · Recovery & Skin Hubs

BPC-157 vs GHK-Cu

Two repair peptides that get lumped together and shouldn't be. One rebuilds internal tissue — tendons, ligaments, gut. The other rebuilds the skin and its structure — collagen, hair, scars. Match the compound to what you're actually trying to heal, and the choice makes itself.

Internal vs SkinTendon/Gut vs Collagen/HairSeparate Syringes Always

The Short Answer

Inside the body vs on the surface

The decision is almost entirely about location. BPC-157 is the internal-repair peptide — tendon, ligament, and gut, driven largely by angiogenesis (new blood-vessel growth). GHK-Cu is the copper peptide for the skin and its architecture — collagen synthesis, hair follicle support, scar remodeling, and post-procedure repair, with the strongest clinical evidence in the aesthetic space. Same word "repair," two different addresses.

Internal Repair

BPC-157

  • Tendon, ligament, gut healing
  • Angiogenic mechanism
  • Extensive animal data, limited human
  • Injectable; can pair with TB-500
vs
Skin & Collagen

GHK-Cu

  • Collagen, skin quality, hair, scars
  • Copper-peptide "smart remodeling"
  • Strongest evidence in the category
  • Topical & post-procedure; solo syringe

Side by Side

The full comparison

Primary targetBPC-157: internal tissue & gutGHK-Cu: skin, collagen, hair
MechanismAngiogenesis, tissue repairCollagen synthesis, remodeling, antioxidant
EvidenceExtensive preclinical, limited humanControlled trials; established cosmetic use
RouteSubcutaneous injectionTopical, post-procedure, or SC (solo)
SyringeMay combine with TB-500Always separate (copper)
Cancer cautionYes — angiogenicPhysician evaluation advised

Which One Fits

Match it to the tissue

BPC-157 if…

  • An internal injury — tendon, ligament, muscle
  • Gut issues or gut-lining concerns
  • Post-surgical internal recovery

GHK-Cu if…

  • Aging skin, collagen loss, texture
  • Hair thinning
  • Scars or post-procedure (microneedling, laser)
Using both after a procedureFor something like a surgery or a skin procedure with deeper healing needs, BPC-157 (internal) and GHK-Cu (surface/scar) can be complementary — but they never share a syringe. GHK-Cu is always solo because of its copper content. Recovery hub → · Skin & Aesthetic hub →

Common Questions

BPC-157 vs GHK-Cu, answered

What's the difference?
BPC-157 heals internal tissue — tendon, ligament, gut — via angiogenesis. GHK-Cu rebuilds skin, collagen, hair, and scars, with the strongest evidence in the aesthetic space. One's internal, one's surface.
Can I use them together?
Yes, as complementary internal + surface repair — but always in separate syringes. GHK-Cu is solo because of its copper content.
Which has better evidence?
GHK-Cu, clearly — decades of controlled research and established cosmetic use. BPC-157 has extensive animal data but limited human data plus a theoretical cancer caution.
Which do I need?
Match the tissue: internal injury or gut → BPC-157; skin, hair, or scars → GHK-Cu. Both carry a cancer caution and need physician oversight.

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on regenerative and aesthetic applications. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked. No products are sold on this site.

Full Disclaimer

BPC-157 is a research compound with limited human data and a theoretical angiogenesis-related cancer caution; GHK-Cu is a cosmetic ingredient and research compound. This page is for educational purposes only and does not constitute medical advice. Any use should be under a licensed physician's supervision, and individuals with a cancer history should exercise particular caution. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.